Category: News
Material developments in peptide science, clinical trials, biotechnology and regulation, reported with dates and primary sources.
Foundayo (Orforglipron): What the October 2026 EMA Opinion Means
On 15 October 2026, the European Medicines Agency’s human medicines committee recommended marketing authorisation for Foundayo (orforglipron) for adult weight management and type 2 diabetes. The…
Read analysis →NSW Peptide Emergency-Department Presentations: What 1,180 Visits Show
NSW Health recorded 1,180 emergency-department presentations mentioning unapproved peptide use between 1 July 2025 and 30 September 2026. The surveillance covered unplanned visits by people aged…
Read analysis →FDA Peptide Compounding Safety Review (2026): BPC-157, TB-500, MOTS-c, CJC-1295 and More
A substance-by-substance guide to the FDA's current peptide compounding safety concerns, including immunogenicity, aggregation, impurities and gaps in human exposure data.
Read analysis →TGA Peptide Enforcement 2026: What the Retatrutide, CJC-1295 and Wolverine Stack Case Shows
The TGA's August 2026 enforcement action illustrates how importing, relabelling and social-media advertising create separate legal and safety risks around unapproved peptides.
Read analysis →CagriSema REIMAGINE 2: What the Published Phase 3 Trial Shows
REIMAGINE 2 published results: HbA1c, safety and trial limits, with sponsor headlines compared against the peer-reviewed phase 3 paper.
Read analysis →Wegovy HD: What the FDA’s 7.2 mg Semaglutide Approval Means—and What It Does Not
The FDA approved a higher-dose semaglutide injection in March 2026. Here is the regulatory fact pattern, safety context and Australian caveat.
Read analysis →FDA Warning on Unapproved GLP-1 Products and “Research Use Only” Marketing
The FDA’s September 2026 GLP-1 warning explains why unapproved, counterfeit and falsely labelled products cannot be treated as equivalents of approved medicines.
Read analysis →TGA Retatrutide Alert: Semaglutide Found in Tested Vial
The TGA says a product sold as retatrutide contained undeclared semaglutide, no retatrutide, and was linked to a serious adverse event. What the 14 September 2026…
Read analysis →